tbuckley/cabot-search huggingface dataset:
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
Authors: Lennard Y W Lee, Jean-Baptiste Cazier, Thomas Starkey, Sarah E W Briggs, Roland Arnold, Vartika Bisht, Stephen Booth, Naomi A Campton, Vinton W T Cheng, Graham Collins, Helen M Curley, Philip Earwaker, Matthew W Fittall, Spyridon Gennatas, Anshita Goel, Simon Hartley, Daniel J Hughes, David Kerr, Alvin J X Lee, Rebecca J Lee, Siow Ming Lee, Hayley Mckenzie, Chris P Middleton, Nirupa Murugaesu, Tom Newsom-Davis, Anna C Olsson-Brown, Claire Palles, Thomas Powles, Emily A Protheroe, Karin Purshouse, Archana Sharma-Oates, Shivan Sivakumar, Ashley J Smith, Oliver Topping, Chris D Turnbull, Csilla Várnai, Adam D M Briggs, Gary Middleton, Rachel Kerr, Abigail Gault, Michael Agnieszka, Ahmed Bedair, Aisha Ghaus, Akinfemi Akingboye, Alec Maynard, Alexander Pawsey, Ali Abdulnabi Suwaidan, Alicia Okines, Alison Massey, Amy Kwan, Ana Ferreira, Angelos Angelakas, Anjui Wu, Ann Tivey, Anne Armstrong, Annet Madhan, Annet Pillai, Ashley Poon-King, Bartlomiej Kurec, Caroline Usborne, Caroline Dobeson, Christina Thirlwell, Christian Mitchell, Christopher Sng, Christopher Scrase, Christopher Jingree, Clair Brunner, Claire Fuller, Clare Griffin, Craig Barrington, Daniel Muller, Diego Ottaviani, Duncan Gilbert, Eliana Tacconi, Ellen Copson, Emily Renninson, Emma Cattell, Emma Burke, Fiona Smith, Francesca Holt, Gehan Soosaipillai, Hayley Boyce, Heather Shaw, Helen Hollis, Helen Bowyer, Iris Anil, Jack Illingworth, Jack Gibson, Jaishree Bhosle, James Best, Jane Barrett, Jillian Noble, Joseph Sacco, Joseph Chacko, Julia Chackathayil, Kathryn Banfill, Laura Feeney, Laura Horsley, Lauren Cammaert, Leena Mukherjee, Leonie Eastlake, Louise Devereaux, Lucinda Melcher, Lucy Cook, Mabel Teng, Madeleine Hewish, Madhumita Bhattacharyya, Mahbuba Choudhury, Mark Baxter, Martin Scott-Brown, Matthew Fittall, Michael Tilby, Michael Rowe, Michael Agnieszka, Mohammed Alihilali, Myria Galazi, Nadia Yousaf, Neha Chopra, Nicola Cox, Olivia Chan, Omar Sheikh, Paul Ramage, Paul Greaves, Pauline Leonard, Peter S Hall, Piangfan Naksukpaiboon, Pippa Corrie, Rahul Peck, Rachel Sharkey, Rachel Bolton, Rebecca Sargent, Rema Jyothirmayi, Robert Goldstein, Roderick Oakes, Rohan Shotton, Ruhi Kanani, Ruth Board, Ruth Pettengell, Ryan Claydon, Sam Moody, Samah Massalha, Sangary Kathirgamakarthigeyan, Saoirse Dolly, Sarah Derby, Sarah Lowndes, Sarah Benafif, Sarah Eeckelaers, Sarah Kingdon, Sarah Ayers, Sean Brown, Shawn Ellis, Shefali Parikh, Sian Pugh, Simon Shamas, Simon Wyatt, Simon Grumett, Sin Lau, Yien Ning Sophia Wong, Sophie McGrath, Stephanie Cornthwaite, Stephen Hibbs, Tania Tillet, Taslima Rabbi, Tim Robinson, Tom Roques, Vasileios Angelis, Victoria Woodcock, Victoria Brown, YingYing Peng, Yvette Drew, Zoe Hudson
Journal: The Lancet Oncology (2020)
The Impact of COVID-19 on Individuals With Intellectual and Developmental Disabilities: Clinical and Scientific Priorities
Authors: John N. Constantino, Mustafa Sahin, Joseph Piven, Rylin Rodgers, John Tschida
Journal: American Journal of Psychiatry (2020)

The goal of this communication is to provide clinicians and behavioral scientists with a scoping perspective on the diverse array of impacts of the COVID-19 pandemic on individuals with intellectual and developmental disabilities (IDD) in the U.S. It is our hope that this will stimulate subsequent scientific and advocacy efforts to ameliorate the disproportionate burden of the pandemic on people with IDD.We begin with the assertion that among non-infected persons in the U.S. few are more adversely affected by COVID-19 than individuals with IDD, given that a vast proportion require in-person care or critical therapeutic support within their living environments, with little back-up or systematic coverage for prolonged interruption of services.Many have temporarily lost access to trained caregivers or community service providers, and now face evolving threats to the return of baseline service, given uncertainties in State and agency budgets.Therefore, a first priority relates to restoration of in-person support services or comparable alternatives.There have been emerging guidelines on the safe care and support of individuals with IDD during the COVID pandemic-see Supplementary Table (ST) 1 which lists resources and documentation of early success of such strategies, however guidance is still evolving, has not permeated all reaches of the community where the information is desperately needed, and is not always presented in ways that can be fully comprehended by those with IDD.It must be
Glis1 facilitates induction of pluripotency via an epigenome–metabolome–epigenome signalling cascade
Authors: Linpeng Li, Keshi Chen, Tianyu Wang, Yi Wu, Guangsuo Xing, Mengqi Chen, Zhihong Hao, Cheng Zhang, Jinye Zhang, Bochao Ma, Zihuang Liu, Hao Yuan, Zijian Liu, Qi Long, Yanshuang Zhou, Juntao Qi, Danyun Zhao, Mi Gao, Duanqing Pei, Jinfu Nie, Dan Ye, Guangjin Pan, Xingguo Liu
Journal: Nature Metabolism (2020)
Considerations for Reduction of Risk of Perioperative Stroke in Adult Patients Undergoing Cardiac and Thoracic Aortic Operations: A Scientific Statement From the American Heart Association
Authors: Mario Gaudino, Curtis Benesch, Faisal Bakaeen, Abe DeAnda, Stephen E. Fremes, Laurent Glance, Steven R. Messé, Aditya Pandey, Lisa Qia Rong
Journal: Circulation (2020)

Perioperative stroke is one of the most severe and feared complications of cardiac surgery. Based on the timing of onset and detection, perioperative stroke can be classified as intraoperative or postoperative. The pathogenesis of perioperative stroke is multifactorial, which makes prediction and prevention challenging. However, information on its incidence, mechanisms, diagnosis, and treatment can be helpful in minimizing the perioperative neurological risk for individual patients. We herein provide suggestions on preoperative, intraoperative, and postoperative strategies aimed at reducing the risk of perioperative stroke and at improving the outcomes of patients who experience a perioperative stroke.
Influence of microscopic malignant peritoneal mesothelioma on posttreatment survival
Authors: M. D. Kluger, J. A. Chabot, M. Hesdorffer, C. M. DeRosa, R. N. Taub
Journal: Journal of Clinical Oncology (2009)

e15534 Background: Progression of malignant peritoneal mesothelioma to clinically evident disease is poorly understood. Operative cytoreduction and post-operative intraperitoneal chemotherapy, followed by a second operative cytoreduction with heated intraoperative intraperitoneal chemotherapy is protocol at Columbia University. Our ability to assess presence of microscopic disease at a unique second operation provides in vivo insight into disease progression. Methods: Operative, pathology and oncologist records were reviewed for 98 consecutive patients with peritoneal mesothelioma treated between 5/95 and 1/08. Microscopic disease was defined as positive pathology on random biopsies in the absence of gross disease at second operation, and disease-free as absence of gross and microscopic disease. Survival was defined as time from first operation to death or last follow-up. Survival and recurrence were compared using the Kaplan Meier and log-rank methods, and correlations by Fisher's exact method. Results: 98 first and 69 second operations were performed. Patients were 59% male, 88% Caucasian and mean age was 52. At the second operation, 38 had gross disease, 23 were disease-free and 8 had microscopic disease. Median follow-up was 21 months, median overall survival was 48 months, and median survival for the epithelial subtype was 64 months. There was no significant difference in survival between disease- free and microscopic pathologies (log-rank p&lt;0.69). 72% of disease-free (SE 11%) and 80% (SE 18%) of those with microscopic disease were alive at 96 months. 16% of disease-free and 7% of patients with microscopic disease had a recurrence (p&lt;0.4). The time to clinical recurrence for both disease-free and microscopic disease was not significantly different (log-rank p&lt;0.88). Conclusions: Survival and clinical recurrence in those with microscopic disease, none of whom were treated for this entity, were not significantly different from those who were disease-free at the second operation. These in vivo after treatment findings suggest that malignant peritoneal mesothelioma may progress slowly from microscopic to clinical disease and can be closely monitored rather than aggressively treated after initial cytoreduction and intraperitoneal chemotherapy. No significant financial relationships to disclose.
OC-073 A comparison of outcomes between a single device lumen-apposing metal stent with electro cautery-enhanced delivery system and a bi-flanged multi-step system metal stent for drainage of walled off pancreatic necrosis
Authors: NL Bekkali, MK Nayar, JS Leeds, RM Charnley, MT Huggett, KW Oppong
Journal: Gut (2017)

Introduction  Recently, purpose designed stents have become available for EUS guided cystgastrostomy and drainage of walled of pancreatic necrosis (WON). The first such stent is a bi-flanged metal stents (BFMS). Bi-flanged metal stents (BFMS) have shown promise in the drainage of walled-off pancreatic necrosis (WON) but require multiple steps and use of other devices for placement. More recently, a novel device consisting of a combined lumen-apposing metals stent (LAMS) and electrocautery-enhanced delivery system has been introduced. This enables a single device to be used when previously multiple devices and steps were required with potential time saving and reduced immediate adverse events.The LAMS is considerably more expensive than the BFMS stent. Studies comparing BFMS to the new generation single step LAMS are lacking.  Aims  To compare procedure time, technical and clinical success, costs and composite endpoint of significant events (adverse events, stent migration, additional percutaneous drainage) between BFMS and LAMS.  Method  Retrospective review of consecutive BFMS/LAMS cases between October 2012 and December 2016, in a prospectively maintained database, undergoing EUS guided drainage of symptomatic WON.  Results  A total of 77 patients underwent consecutive BFMS (44) and LAMS (33) placement. Successful placement was achieved in 91% BFMS and 97% LAMS. Median [range] in-room procedure time was significantly shorter (45 [30-80] minutes vs 62.5 [35-135], p  Conclusion  The LAMS was superior to the BFMS in terms of procedure time with comparable adverse events, success and costs.  Disclosure of Interest  None Declared
In a search for efficient treatment for amyotrophic lateral sclerosis: Old drugs for new approaches
Authors: Michail S. Kukharsky, Veronika I. Skvortsova, Sergey O. Bachurin, Vladimir L. Buchman
Journal: Medicinal Research Reviews (2020)

Recent progress in understanding the pathological changes in the nervous system and in certain other body systems (e.g., immune system) that lead to the development and progression of amyotrophic lateral sclerosis (ALS) revealed a number of molecular and cellular processes that can potentially be used as therapeutic targets. Many of these processes are compromised not only in ALS but also in other diseases and a repertoire of drugs able to restore, at least partially, their functionality has been developed. In this review, we briefly describe current approaches to the repurposing of such "old" drugs for treatment of patients with ALS.
Getting a second opinion: whose side are you on?
Authors: Dominic de Takats
Journal: BMJ (2020)

Helen Salisbury asks, “When the specialist’s view is that there is nothing more that can be done, how ready should I be to refer for a second opinion?”1 This question is packed with implied hints about trusting the specialist involved; being seen to question their judgment, thereby risking professional relationships; and wondering how tempered …
Response to: ‘Case of postpartum axial spondyloarthritis’ by Furuhashi<i>et al</i>
Authors: Adel Hoballah, Cédric Lukas, Christophe Leplat, Patrice Taourel, Jean-Baptiste Pialat, Nicolas Sans, Sonia Ramos-Pascual, Mo Saffarini, Catherine Cyteval
Journal: Annals of the Rheumatic Diseases (2020)

Response to: 'Case of postpartum axial spondyloarthritis' by Furuhashi et alWe were pleased to read the correspondence of Furuhashi et al 1 who highlighted the importance of considering coexisting risk factors when diagnosing axial spondyloArthritis (ax-SpA) in early postpartum women.The authors correctly pointed out that patients with inflammatory bowel disease are more likely to develop ax-SpA due to common pathogenic mechanisms. 2 In fact, the presence of Crohn's disease or ulcerative colitis is part of the Assessment of SpondyloArthritis international Society criteria for the diagnosis of ax-SpA. 3n our study, on the prevalence of bone marrow oedema (BME) at the sacroiliac joint (SIJ) in postpartum women, 4 we excluded those with known risk factors for developing ax-SpA, such as family or patient history of inflammatory diseases.The exclusion of women with known risk factors for developing ax-SpA was deemed important to eliminate potential confounding factors, and hence ascertain whether observations of sacroiliitis were triggered by, or related to, pregnancy and childbirth as opposed to other aetiologies.In our experience, women with inflammatory bowel disease who have low back pain within the first 6 months after delivery should be assessed using MRI to identify the causes of pain, which could include infections or degenerative diseases.However, we believe that BME at the SIJ observed in an MRI taken during the early postpartum period is insufficient to diagnose ax-SpA, since BME at the SIJ may be merely transient and could disappear over time.It is also important to note the limitations of MRI for the diagnosis of ax-SpA, due to limited sensitivity and specificity of detecting 'suggestive BME' lesions, and the role/necessity of conventional radiography for the standardisation and contextual evaluation. 5While response to tumour necrosis factor inhibitors, such as adalimumab, can confirm diagnosis and relieve symptoms, immunosuppressive drugs are associated with a number of adverse events.We endeavour to improve the efficacy of clinical and imaging diagnostic tools to prescribe the most appropriate treatment and avoid such adverse events, especially in patients that are unlikely to benefit from immunosuppressive drugs.
Preventing and Mitigating SARS-CoV-2 Transmission — Four Overnight Camps, Maine, June–August 2020
Authors: Laura L. Blaisdell, Wendy Cohn, Jeff R. Pavell, Dana S. Rubin, Jeffrey E. Vergales
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

public and private schools affected at least 55.1 million students through the end of the 2019-20 school year.† During the summer of 2020, approximately 82% of 8,947 U.S. overnight camps did not operate.§ In Maine, only approximately 20% of 100 overnight camps opened.¶ An overnight camp in Georgia recently reported SARS-CoV-2, the virus that causes COVID-19, transmission among campers and staff members when nonpharmaceutical interventions (NPIs) were not strictly followed (1); however, NPIs have been successfully used to mitigate SARS-CoV-2 transmission among military basic trainees (2).During June-August 2020, four overnight camps in Maine implemented several NPIs to prevent and mitigate the transmission of SARS-CoV-2, including prearrival quarantine, pre-and postarrival testing and symptom screening, cohorting, use of face coverings, physical distancing, enhanced hygiene measures, cleaning and disinfecting, and maximal outdoor programming.During the camp sessions, testing and symptom screening enabled early and rapid identification and isolation of attendees with COVID-19.Among the 1,022 attendees (staff members and campers) from 41 states, one territory, and six international locations, 1,010 were tested before arrival; 12 attendees who had completed a period of isolation after receiving a diagnosis of COVID-19 2 months before arrival were not tested.Four (0.4%) asymptomatic attendees received positive SARS-CoV-2 test results before arrival; these persons delayed their arrival, completed 10 days of isolation at home, remained asymptomatic, and did not receive any further testing before arrival or for the duration of camp attendance.Approximately 1 week after camp arrival, all 1,006 attendees without a previous diagnosis of COVID-19 were tested, and three asymptomatic cases were identified.Following isolation of these persons and quarantine of their contacts, no secondary transmission of SARS-CoV-2 occurred.These findings can inform similar multilayered public health strategies to prevent and mitigate the introduction and transmission of SARS-CoV-2 among children, * https://www.who.int/dg/speeches/detail/who-director-general-s-openingremarks
Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment
Authors: Takumi Kobayashi, Pui Yeng Lam, Hui Jiang, Karolina Bednarska, Renee Gloury, Valentine Murigneux, Joshua Tay, Nicolas Jacquelot, Rui Li, Zewen Kelvin Tuong, Graham R. Leggatt, Maher K. Gandhi, Michelle M. Hill, Gabrielle T. Belz, Shyuan Ngo, Axel Kallies, Stephen R. Mattarollo
Journal: Blood (2020)
Platelet membrane-functionalized nanoparticles with improved targeting ability and lower hemorrhagic risk for thrombolysis therapy
Authors: Songli Wang, Ruifeng Wang, Nana Meng, Haiyan Guo, Sunyi Wu, Xiaoyi Wang, Jinyang Li, Huan Wang, Kuan Jiang, Cao Xie, Yu Liu, Hao Wang, Weiyue Lu
Journal: Journal of Controlled Release (2020)
Recent advances of sorafenib nanoformulations for cancer therapy: Smart nanosystem and combination therapy
Authors: Fangmin Chen, Yifan Fang, Xiang Chen, Rui Deng, Yongjie Zhang, Jingwei Shao
Journal: Asian Journal of Pharmaceutical Sciences (2020)

Sorafenib, a molecular targeted multi-kinase inhibitor, has received considerable interests in recent years due to its significant profiles of efficacy in cancer therapy. However, poor pharmacokinetic properties such as limited water solubility, rapid elimination and metabolism lead to low bioavailability, restricting its further clinical application. Over the past decade, with substantial progress achieved in the development of nanotechnology, various types of smart sorafenib nanoformulations have been developed to improve the targetability as well as the bioavailability of sorafenib. In this review, we summarize various aspects from the preparation and characterization to the evaluation of antitumor efficacy of numerous stimuli-responsive sorafenib nanodelivery systems, particularly with emphasis on their mechanism of drug release and tumor microenvironment response. In addition, this review makes great effort to summarize the nanosystem-based combination therapy of sorafenib with other antitumor agents, which can provide detailed information for further synergistic cancer therapy. In the final section of this review, we also provide a detailed discussion of future challenges and prospects of designing and developing ideal sorafenib nanoformulations for clinical cancer therapy.
Brain metastases in breast cancer: Different survival by biological subtype and Ki67 expression
Authors: D. Sartori, M. Bari, G. L. Pappagallo, F. Rosetti, S. Olsen, O. Vinante
Journal: Journal of Clinical Oncology (2009)

1069 Background: Ten to 15% of patients (pts) with breast cancer will be diagnosed with central nervous system (CNS) metastases, and autopsy series suggest that up to 30% of pts have evidence of CNS disease at the time of death. The idenfication of factors that may predispose to CNS metastasis may help lead to earlier detection and possibly to improvement in disease management. Methods: Breast cancer pts with CNS metastases were identified within a database of 1300 breast cancer diganoses from 1995 to 2007 at the Department of Oncology, Azienda ULSS 13 VE. Pathologic features of tumor samples were examined using standard immunohistochemical assays. Results: Fifty-one pts with CNS metastases were identified. Median age at primary breast cancer diagnosis was 49 years (range, 28–78); median time to CNS metastases was 45 months (range, 3–244). HER2 overexpression was found in tumors from 25 pts (49.0%); 23 pts had tumors lacking overexpression of HER2, estrogen receptors (ER), and progesterone receptors (PgR) (ie, “triple negative” disease). Overexpression of p53 (at least 20% tumor cells positive), Ki67 (at least 20%), and BCL2 (at least 30%) were detected in tumors from 16 pts (31.4%), 32 pts (62.7%), and 14 pts (27.5%), respectively. Median survival from CNS involvement was 3.67 months (95% CI 2.05–5.28), with 24.4% and 15.3% of patients estimated to be alive at 12 and 24 months, respectively (Kaplan-Meier product limit method). A Cox proportional hazards analysis found that Ki67 overexpression was the only factor independently associated with a significantly increased risk of death (2.7-fold increase, p=0.028), while triple negative status was associated with a 1.8-fold increase in the risk of death (P=0.08) (Table). Conclusions: In our series of breast cancer pts with CNS metastases, nearly all had either HER2 overexpression or triple-negative disease. Pts whose tumors had higher proliferative indices, assessed by Ki67, had the poorest prognosis. [Table: see text] [Table: see text]
Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa
Authors: Da Meng, Sara D. Ragi, Stephen H. Tsang
Journal: Molecular Therapy (2020)

Rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) is a hereditary degenerative disorder in which mutations in the gene encoding RHO, the light-sensitive G protein-coupled receptor involved in phototransduction in rods, lead to progressive loss of rods and subsequently cones in the retina. Clinical phenotypes are diverse, ranging from mild night blindness to severe visual impairments. There is currently no cure for RHO-adRP. Although there have been significant advances in gene therapy for inherited retinal diseases, treating RHO-adRP presents a unique challenge since it is an autosomal dominant disease caused by more than 150 gain-of-function mutations in the RHO gene, rendering the established gene supplementation strategy inadequate. This review provides an update on RNA therapeutics and therapeutic editing genome surgery strategies and ongoing clinical trials for RHO-adRP, discussing mechanisms of action, preclinical data, current state of development, as well as risk and benefit considerations. Potential outcome measures useful for future clinical trials are also addressed.
Abstract 20581: Obesity’s Outsized Role in Sudden Cardiac Arrest With HFpEF
Authors: Kyndaron Reinier, Carmen Rusinaru, Audrey Uy-Evanado, Aapo Aro, Eric C Stecker, Gregory Nichols, Karen Gunson, Jonathan Jui, Sumeet S Chugh
Journal: Circulation (2017)

Introduction: Heart failure with preserved ejection fraction (HFpEF) is associated with increased risk of mortality, including sudden cardiac arrest (SCA). Obesity may play a role in the morbidity ...
Cutaneous squamous cell carcinoma of the forearm: Clinical features and outcomes at a single academic tertiary care center in a rural setting
Authors: Margaret Johnston, Cari E. Carpenter, Kathryn Potter, Maxwell Knapp, Katelyn Shea, David J. Seward, Caitlyn Dayman, Melanie R. Bui
Journal: Journal of the American Academy of Dermatology (2020)